← Anika Therapeutics, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss) Attributable to Parent | $32.5m |
$31.8m
-2.25%
|
$18.7m
-41.16%
|
$27.2m
+45.25%
|
($24.0m)
-188.19%
|
$4.1m
+117.24%
|
($14.9m)
-459.43%
|
($82.7m)
-456.34%
|
($56.4m)
+31.79%
|
($10.9m)
+80.70%
|
— | |
| Depreciation and amortization | $3.7m | $4.3m | $5.9m | $6.0m | $13.5m | $6.5m | $6.7m | $6.4m | $6.9m | $5.4m | $5.6m | |
| Depreciation | $2.7m | $3.3m | $4.9m | $5.0m | $6.1m | $6.5m | $6.7m | $6.4m | $5.0m | $5.4m | $5.6m | |
| Amortization of Intangible Assets | $1.1m | $1.0m | $1.0m | $1.0m | $7.4m | $7.8m | $7.8m | $7.8m | $700k | $400k | — | |
| Deferred Income Tax Expense (Benefit) | ($65k) | ($1.2m) | ($1.8m) | $794k | ($3.5m) | ($1.8m) | ($5.3m) | ($6.3m) | $260k | ($7k) | $215k | |
| Share-based Payment Arrangement, Noncash Expense | $3.4m | $5.8m | $11.0m | $6.1m | $5.4m | $11.1m | $14.3m | $15.2m | $13.1m | $10.1m | $13.1m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | $1.8m | $293k | $262k | $486k | $934k | $2.2m | $2.6m | $1.6m | — | |
| Share-based Payment Arrangement, Expense | $3.4m | $5.8m | $11.0m | $6.1m | $5.4m | $11.1m | $14.3m | $15.2m | $12.2m | $10.2m | $13.1m | |
| Goodwill and Intangible Asset Impairment | — | — | — | — | — | — | — | $62.2m | — | — | — | |
| Goodwill, Impairment Loss | — | — | — | — | $42.5m | $0 | $0 | — | — | — | $0 | |
| Impairment of Intangible Assets, Finite-lived | — | — | — | $389k | $2.4m | $600k | $0 | $62.2m | $2.5m | — | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | $6.2m | ($2.7m) | ($2.9m) | $1.8m | ($5.9m) | $6.2m | $5.6m | $1.3m | ($3.4m) | ($408k) | ($5.7m) | |
| Increase (Decrease) in Inventories | $1.7m | $6.5m | $7.6m | $5.6m | $14.2m | $6.6m | $6.9m | $11.4m | $9.4m | ($30k) | ($13.6m) | |
| Inventory Write-down | $654k | $695k | $4.4m | $1.6m | $5.5m | $6.6m | $5.3m | $3.3m | $44.7m | $5.8m | — | |
| Increase (Decrease) in Accounts Payable | ($5.1m) | $3.9m | ($1.7m) | $767k | $822k | ($1.1m) | $2.0m | ($11k) | ($2.5m) | $42k | $1.3m | |
| Net Cash Provided by (Used in) Operating Activities | $23.8m |
$40.8m
+71.47%
|
$34.9m
-14.44%
|
$37.0m
+5.98%
|
$13.1m
-64.69%
|
$8.4m
-35.73%
|
$4.4m
-47.49%
|
($1.8m)
-140.55%
|
$5.4m
+402.18%
|
$11.2m
+107.07%
|
$6.0m
-46.58%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $14.0m | $9.0m | $4.7m | $2.8m | $1.6m | $5.1m | $7.5m | $5.4m | $7.7m | $6.8m | ($5.4m) | |
| Gain (Loss) on Disposition of Property Plant Equipment | — | ($150k) | ($152k) | ($927k) | ($265k) | ($993k) | $0 | ($1.9m) | ($2.9m) | $166k | $255k | |
| Gain (Loss) on Investments | — | — | $371k | $25k | ($13k) | — | — | — | — | — | — | |
| Payments to Acquire Businesses, Net of Cash Acquired | — | — | — | — | $94.6m | $476k | $0 | $0 | — | — | — | |
| Net Cash Provided by (Used in) Investing Activities | ($6.8m) | ($12.5m) | ($50.3m) | $39.7m | ($71.3m) | ($3.1m) | ($7.5m) | ($5.4m) | ($8.3m) | ($401k) | ($4.1m) | |
| Cash flows from financing activities: | ||||||||||||
| Repayments of Long-term Debt | — | — | — | — | $50.4m | $0 | $0 | — | — | — | $0 | |
| Proceeds from Issuance of Long-term Debt | — | — | — | — | $50.0m | $0 | $0 | — | — | — | $0 | |
| Payments for Repurchase of Common Stock | $25.0m | — | $30.0m | $30.0m | $0 | $0 | — | $5.0m | $10.9m | $9.5m | — | |
| Net Cash Provided by (Used in) Financing Activities | ($23.3m) |
$314k
+101.34%
|
($28.9m)
-9305.10%
|
($8.1m)
+71.83%
|
($3.8m)
+53.65%
|
($6.8m)
-79.62%
|
($4.9m)
+28.43%
|
($6.3m)
-30.34%
|
($12.7m)
-101.28%
|
($10.6m)
+17.11%
|
($16.3m)
-54.87%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | ($138k) | $349k | $29k | ($133k) | ($61.6m) | ($1.4m) | ($8.1m) | ($13.5m) | ($15.7m) | $322k | $38.8m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | $1.0m | $314k | $2.9m | $22.2m | $1.5m | $1.1m | $16k | $23k | $76k | $0 | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, Net | $22.8m | $15.1m | $5.6m | $9.3m | $993k | $1.2m | $106k | $3.1m | $4.0m | $1.1m | — | |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before Tax | ($300k) | $700k | ($400k) | — | $300k | ($400k) | ($500k) | $100k | ($200k) | ($400k) | — | |
| Goodwill | $7.2m | $8.2m | $7.9m | $7.7m | $8.4m | $7.8m | $7.3m | $7.6m | $7.1m | $8.1m | $0 | |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | — | — | — | — | — | — | — | — | ($8.8m) | ($10.0m) | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | — | — | — | — | — | — | — | ($901k) | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | — | — | — | — | — | — | — | — | ($47.6m) | ($901k) | — | |
| Income Tax Expense (Benefit) | $18.3m | $14.4m | $4.5m | $8.9m | ($4.6m) | ($1.7m) | ($3.9m) | ($2.7m) | $6.1m | $672k | — |